$ELDN's tegoprubart showed positive Phase 2 kidney transplant results: 12-month mean eGFR improvement reported. www.biopharmcatalyst.com/news/2025/pu...

BioPharmCatalyst Weekly Watchlist: Key Phase 3 catalysts for $MESO, $SLS, $MGTX, $XOMA, $BLTE, $IMVT, $CAPR, $ERAS, $CGON, $CGEM. Stay updated on biotech moves! #biotech #Watchlist www.biopharmcatalyst.com/news/2025/bi...

$GMED gets Hold from Needham & Stifel after Q3 beat; U.S. Spine strong, but leasing pressure weighs. Stifel PT: $64. www.biopharmcatalyst.com/news/2025/gl...

$URGN’s UGN-103 hit 77.8% 3-mo CR in Phase 3 UTOPIA, matching prior data; FDA says results support NDA submission. Key regulatory milestone. www.biopharmcatalyst.com/news/2025/io...

$RXST beat Q3 revenue estimates with $30.3M vs. $25.3M expected, despite a 14% YoY drop. $SGMO $PACB $ESPR $NMRA $PHAR $PEN $VCEL $LNAI $SNN among notable pre-market movers. www.biopharmcatalyst.com/news/2025/sa...

$LNAI’s 2nd-gen dendritic cell therapy showed full tumor regression in mouse models of pancreatic cancer, boosting its clinical outlook. www.biopharmcatalyst.com/news/2025/lu...

$BHVN drops premarket after FDA rejects Vyglxia (troriluzole) approval. $SLNO $NPCE $RDHL $RIGL $PSNL $VCYT $CDNA $CNTA $AKTX movers. www.biopharmcatalyst.com/news/2025/bi...

$PRLD will prioritize its mutant-selective JAK2V617F inhibitor and KAT6A degrader programs while pausing clinical development of its SMARCA2-selective degraders. $EVOK $PRLD $ARTL $RLMD $NCEL $TCMD $TERN $CSTL $AIM $ADTX See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/pr...

$EVOK to be acquired by QOL Medical for $11/share, a 139.7% premium. Deal closes by end of 2025. $EVOK $PRLD $SRPT $TCMD $CMPS $HRTX $ACOG $ABP $STIM $CLNN www.biopharmcatalyst.com/news/2025/ev...

$CRBP plans a public offering to fund oncology/obesity pipeline. Jefferies & Piper Sandler are bookrunners. 30-day option for extra shares. www.biopharmcatalyst.com/news/2025/pr...

$PHIO Phase 1b: PH-762 showed ≥50% tumor clearance in 10/18 cSCC patients, no toxicities, with one 100% cleared. Promising non-surgical option for skin cancer. www.biopharmcatalyst.com/news/2025/ph...

$CRBP plans stock/warrant offering to fund oncology & obesity programs; Jefferies & Piper Sandler are bookrunners with a 30-day 15% upsizing option. www.biopharmcatalyst.com/news/2025/ne...

BioPharmCatalyst Weekly Watchlist: Top biotech stocks & key catalysts to watch ($RGNX, $REPL, $SNY, $ALDX, $NKTR & more). Stay updated on news & movers! www.biopharmcatalyst.com/news/2025/bi...

$ATEC Q3 revenue up 30% YoY to $197M, adj. EBITDA $26M. Raised 2025 guidance: $760M revenue, $91M EBITDA. Strong surgeon adoption, positive cash flow. www.biopharmcatalyst.com/news/2025/al...

$ADTX announces 1-for-113 reverse split effective Nov 3, 2025, to meet Nasdaq requirements. Symbol remains unchanged. #BiotechUpdate www.biopharmcatalyst.com/news/2025/er...

$INTS published phase 1/2 results on INT230-6 for advanced cancers: 75% disease control, 11.9 mo median survival. Study in eBioMedicine. www.biopharmcatalyst.com/news/2025/ce...

$ERNA partners with Cellipont for cGMP manufacturing of ERNA-101, aiming to make ovarian tumors more responsive to immunotherapy. Strong preclinical results. www.biopharmcatalyst.com/news/2025/er...

$PPBT hits manufacturing milestone for IM1240 tri-specific antibody, boosting safety/efficacy against tumor evasion. High-yield, high-purity process achieved. $AKBA $GNTA $NLSP $RNTX $BBIO www.biopharmcatalyst.com/news/2025/pu...

$ARQT reported third-quarter ZORYVE revenue of $99.2M, up 122% YoY and 22% QoQ, driven by broad adoption. ZORYVE cream 0.05% for pediatric atopic dermatitis launches by the end of October following FDA approval. See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/ar...

$SBFM gains on Health Canada nod for Domperidone via Nora Pharma, targeting Canada’s $533M market. Boosts generic drug portfolio. #Premarket #Stocks www.biopharmcatalyst.com/news/2025/su...

$RNA to be acquired by Novartis for $72/share in $12B deal; 46% premium. Spin-off early cardiology assets into SpinCo. www.biopharmcatalyst.com/news/2025/av...

$GNTA expands ANEMOCYTE partnership to commercialize scalable LVV plasmid DNA tech for advanced therapies. $NTLA $RNA $NBTX $ZBIO $KZIA $DYN $NMRA $OGN $NRXS www.biopharmcatalyst.com/news/2025/ge...

$INBX's ozekibart met its main goal in a chondrosarcoma trial, with strong PFS results; BLA filing in Q2 2026. Promising interim data in colorectal & Ewing sarcoma also reported. www.biopharmcatalyst.com/news/2025/in...

BioPharmCatalyst Weekly Watchlist: Top biotech stocks & key catalysts to watch. Highlights: $COGT $RZLT $DVBT $BLTE $IMVT $PCVX. More in our newsletter. www.biopharmcatalyst.com/news/2025/bi...

$GNTA expands ANEMOCYTE deal to commercialize plasmid DNA tech, boosting scalable advanced therapy solutions. $GNTA $NRXS $COYA $QLGN $INBX $GNPX $NEUP $FEMY $GELS $IVA www.biopharmcatalyst.com/news/2025/ge...

$ITGR Q3: Revenue up 8% to $468M, EPS +25%, adjusted EBITDA +11%. Full-year guidance cut; Q4 growth to slow. Debt/leveraged up after acquisitions. www.biopharmcatalyst.com/news/2025/ve...

$VTYX up on Phase 2 VTX3232 data: up to 78% hsCRP drop, improved inflammation markers, but no added weight loss vs. semaglutide. $VTYX $IBIO $TNGX $GNPX $NLSP www.biopharmcatalyst.com/news/2025/ve...

$ARMP's IV phage therapy for S. aureus showed 88% response vs 58% placebo in Phase 2a, supporting Phase 3 move. First randomized data for IV phage in SAB. #biotech www.biopharmcatalyst.com/news/2025/ar...

$ARCT up on positive Phase 2 data for inhaled CF therapy—safe, early signs of benefit. 12-week study in 2026 planned. $ARCT $ALEC $BNBX $NRIX $TERN $OWLT $RANI $DRTS $SNOA $PCSA www.biopharmcatalyst.com/news/2025/ar...

$NERV gets $200M financing ($80M upfront) for Phase 3 roluperidone trial in schizophrenia; FDA approved design. Board expansion aims to boost execution. www.biopharmcatalyst.com/news/2025/mi...

$IBIO to present new data at ObesityWeek/PEGS Europe on IBIO-610 for obesity, highlighting fat-selective weight loss and synergy with GLP-1s. www.biopharmcatalyst.com/news/2025/ib...

$ANRO announced a successful FDA meeting supporting accelerated development of ALTO-207 for treatment-resistant depression, with a $50 million private placement expected to fund a Phase 3 trial launch by early 2027. See More Biotech Updates👇 www.biopharmcatalyst.com/news/2025/re...

$KZR downgraded to Hold at Jefferies, PT cut to $7 (from $18) after Phase 3 FDA setback for zetomipzomib; company exploring options, future now uncertain. www.biopharmcatalyst.com/news/2025/re...

$REPL up as FDA accepts RP1 BLA resubmission for advanced melanoma; PDUFA date set for April 10, 2026. www.biopharmcatalyst.com/news/2025/re...

$KZR downgraded to Hold by Jefferies, PT cut to $7 after FDA setback on zetomipzomib. Kezar now exploring strategic options, adding uncertainty. www.biopharmcatalyst.com/news/2025/ar...

BioPharmCatalyst Watchlist: Top biotech stocks to watch—key Phase 1/2 catalysts in the next 6 months. $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM www.biopharmcatalyst.com/news/2025/bi...

$RANI inks $1.085B Chugai deal, gets $10M upfront plus milestones. With $60.3M raise, now funded into 2028 to advance oral biologics. $ARTV $XRTX $KZR $ACHV $PLX $AKAN $IRON $RCEL $NIVF www.biopharmcatalyst.com/news/2025/ra...

$TOVX raises $4M via warrant inducement; investors get new 5-year warrants at $0.54 pending approval. #biotech www.biopharmcatalyst.com/news/2025/pr...

$PRAX reports positive Phase 3 results for ulixacaltamide in essential tremor, showing improved tremor control and daily function. #PremarketMovers www.biopharmcatalyst.com/news/2025/pr...

$OMER sells OMS906 rights to Novo Nordisk for $340M upfront, total deal up to $2.1B plus royalties. Novo gets full control for rare blood and kidney disorder treatments. www.biopharmcatalyst.com/news/2025/ge...

$GNPX: Reqorsa shows strong preclinical efficacy in ALK-EML4+ NSCLC; data to be presented at AACR-NCI-EORTC. Supports use with ALK inhibitors. www.biopharmcatalyst.com/news/2025/ge...

$GNPX’s Reqorsa shows strong preclinical results in ALK-EML4+ NSCLC models. More biotech news: $ATXS $NDRA $RCKT $GDTC $SBFM $EVAX $SNTI $CERO $IVVD. www.biopharmcatalyst.com/news/2025/as...

$BCRX to acquire $ATXS for $13/share in cash & stock, valuing $ATXS at ~$700M. Deal expands BioCryst’s immunology portfolio. #PremarketMovers www.biopharmcatalyst.com/news/2025/bi...

$NDRA raises $4.9M via private placement to fund Arca-backed DeFi treasury, shifting focus toward blockchain assets while maintaining imaging tech. www.biopharmcatalyst.com/news/2025/tv...

$TVRD drops after Phase 2 trial for TTI-101 in IPF misses goals; no FVC benefit, more GI side effects. Focus shifts to TTI-109, HCC trial ongoing. www.biopharmcatalyst.com/news/2025/tv...

BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and regulatory catalysts for the next 6 months $COGT $RZLT $DBVT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM biopharmcatalyst.com/news/2025/bi...

$QNRX inks deal with healthcare investors: raises $16.5M upfront, up to $104.5M total with warrants. #BiotechUpdates www.biopharmcatalyst.com/news/2025/qu...

$SHPH to acquire Molecule.ai for $10M, boosting AI-driven drug discovery and streamlining therapeutic development. $SHPH $CARM $ARAY $CDT $ATYR $CDTX $ADTX $LITS $IVA $KIDS www.biopharmcatalyst.com/news/2025/ca...

$BJDX expands SanyoSeiko partnership for rapid sepsis test (IL-6, 20min), awaits FDA nod. Announces $2M private placement; new warrants exercisable at $1.75. $BJDX #biotech www.biopharmcatalyst.com/news/2025/bl...

$CDT plans 1-for-8 reverse split to boost capital-raising, per board approval and May 2025 shareholder OK. www.biopharmcatalyst.com/news/2025/bl...